
handle: 11449/64491
Purpose - To evaluate the adverse reactions of fosinopril with other antihypertensives used as monotherapy. Methods - Out-patients (n = 2,568) with diagnostic of mild to moderate hypertension, diastolic blood pressure (DBP) 95-115 mmHg, with no antihypertensive treatment for 15 days, were included to treatment initially with fosinopril (F) 10mg, once daily, for six weeks. After this period, patients with DBP >95mmHg had the dosage, once daily, increased to 20 mg, while the others were maintained with the same dosage for six more weeks. Adverse reactions of 822 patients treated as monotherapy were grouped as absent, musculoskeletal, cardiovascular, cough, gastrointestinal, neurological, genital-urinary dysfunctions and dermatological and compared with 1,568 with F. Monotherapy consist in α-methyldopa (100 patients); β-blocker (129); calcium blocker (106); diuretic (394); and another ACE inhibitors (93). Results - At the end of the period without treatment, the blood pressure (BP), 165 ± 16/105 ± 7 mmHg decreased significantly at 6(th) week to 144 ± 15/91 ± 9 mmHg (p < 0.05 vs week 0) with further lowering to 139 ± 13/86 ± 7 mmHg till the end of 12(th) week. BP response (DBP ≤90 mmHg) was obtained in 89% of the patients with F. Absence of adverse reactions were ≥70% in patients with F compared to other drugs. Conclusion - Fosinopril has demonstrated therapeutic efficacy and less adverse reactions compared to antihypertensives used previously as monotherapy.
Adult, Male, hypertension, musculoskeletal injury, Adolescent, cardiotoxicity, gastrointestinal symptom, oral drug administration, 610, fosinopril, methyldopa, English Abstract, Middle Age, male, ambulatory care, dipeptidyl carboxypeptidase inhibitor, neurotoxicity, 80 and over, Ambulatory Care, controlled study, Comparative Study, human, coughing, comparative study, Antihypertensive Agents, Aged, Aged, 80 and over, controlled clinical trial, diuretic agent, adult, blood pressure, beta adrenergic receptor blocking agent, clinical trial, major clinical study, skin toxicity, drug efficacy, aged, female, multicenter study, adolescent, Hypertension, calcium antagonist, antihypertensive agent, Female, Fosinopril, angiotensin converting enzyme inhibitor, Human
Adult, Male, hypertension, musculoskeletal injury, Adolescent, cardiotoxicity, gastrointestinal symptom, oral drug administration, 610, fosinopril, methyldopa, English Abstract, Middle Age, male, ambulatory care, dipeptidyl carboxypeptidase inhibitor, neurotoxicity, 80 and over, Ambulatory Care, controlled study, Comparative Study, human, coughing, comparative study, Antihypertensive Agents, Aged, Aged, 80 and over, controlled clinical trial, diuretic agent, adult, blood pressure, beta adrenergic receptor blocking agent, clinical trial, major clinical study, skin toxicity, drug efficacy, aged, female, multicenter study, adolescent, Hypertension, calcium antagonist, antihypertensive agent, Female, Fosinopril, angiotensin converting enzyme inhibitor, Human
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
